Gaisler-Salomon Inna, Kravitz Efrat, Feiler Yulia, Safran Michal, Biegon Anat, Amariglio Ninette, Rechavi Gideon
Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; The Joseph Sagol Neuroscience Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Neurobiol Aging. 2014 Aug;35(8):1785-91. doi: 10.1016/j.neurobiolaging.2014.02.018. Epub 2014 Mar 1.
Adenosine to inosine (A-to-I) RNA editing is a base recoding process within precursor messenger RNA, catalyzed by members of the adenosine deaminase acting on RNA (ADAR) family. A notable example occurs at the Q/R site of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor subunit GluA2. Abnormally, low editing at this site leads to excessive calcium influx and cell death. We studied hippocampus and caudate samples from Alzheimer's disease (AD) patients and age-matched healthy controls, using direct sequencing and a high accuracy primer-extension technique to assess RNA editing at the Q/R GluA2 site. Both techniques revealed lower, more variable RNA editing in AD, specific to the hippocampus and the GluA2 site. Deficient editing also characterized the hippocampus of apolipoprotein ε4 allele carriers, regardless of clinical diagnosis. In AD, messenger RNA expression of neuronal markers was decreased in the hippocampus, and expression of the Q/R-site editing enzyme ADAR2 was decreased in caudate. These findings provide a link between neurodegenerative processes and deficient RNA editing of the GluA2 Q/R site, and may contribute to both diagnosis and treatment of AD.
腺苷到肌苷(A-to-I)的RNA编辑是前体信使RNA内的碱基重新编码过程,由作用于RNA的腺苷脱氨酶(ADAR)家族成员催化。一个显著的例子发生在α-氨基-3-羟基-5-甲基-4-异恶唑丙酸谷氨酸受体亚基GluA2的Q/R位点。异常的是,该位点的低编辑会导致过多的钙内流和细胞死亡。我们使用直接测序和高精度引物延伸技术,研究了阿尔茨海默病(AD)患者和年龄匹配的健康对照者的海马体和尾状核样本,以评估Q/R GluA2位点的RNA编辑情况。两种技术均显示,AD患者中RNA编辑较低且更具变异性,这在海马体和GluA2位点具有特异性。编辑缺陷也是载脂蛋白ε4等位基因携带者海马体的特征,无论其临床诊断如何。在AD患者中,海马体中神经元标志物的信使RNA表达降低,尾状核中Q/R位点编辑酶ADAR2的表达降低。这些发现揭示了神经退行性变过程与GluA2 Q/R位点RNA编辑缺陷之间的联系,可能有助于AD的诊断和治疗。